Mozart Therapeutics Launches With $55 Million Series A Financing To Develop Disease Modifying Therapeutics For Autoimmune And Inflammatory Diseases
Mozart Therapeutics Launches With $55 Million Series A Financing To Develop Disease Modifying Therapeutics For Autoimmune And Inflammatory Diseases
10/26/21, 8:00 AM
Location
seattleMoney raised
$55 million
Round Type
series a
Mozart Therapeutics, Inc., a new biopharmaceutical company targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announced a $55 Million Series A Financing led by seed and Series A investor ARCH Venture Partners along with Sofinnova Partners. Additional investors include Eli Lilly & Company, MRL Ventures Fund (the early-stage therapeutics-focused fund of Merck & Co., Inc.), Leaps by Bayer, Altitude Life Science Ventures, Alexandria Venture Investments.
Company Info
Location
seattle, washington, united states
Additional Info
Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway. The therapeutic focus of Mozart's lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.
1Saligrama N, Davis MM et al., Nature 2019: https://doi.org/10.1038/s41586-019-1467-x